Current position

BlackRock, Inc.’s AbbVie (ABBV) position

Reported position history, portfolio importance and verified filing changes from public SEC disclosures.

BlackRock, Inc.Verified through Q2 2026
Relationship snapshot

At a glance

The full verified relationship, including prior ownership episodes and exits where supported.

First reportedQ3 2016Earliest verified positive filing snapshot
Latest statusCurrent positionBased on the latest supported relationship state
Peak shares151.17MHighest verified quarter-end share count
Quarters reported40Verified quarters with shares above zero
What happened?

BlackRock, Inc. first reported AbbVie in Q3 2016. The reported position was increased and reduced across later filings. BlackRock, Inc. currently reports 149.49M shares. The latest verified filing showed: Sold 0.8% of the position.

Verified SEC history

Position over time

See the same verified relationship through reported shares, portfolio weight or reported value.

Metric

Gaps indicate periods that cannot be safely connected or where a verified corporate action changes the raw share scale. Stock price, when available, is market context and not a transaction price.

Key filing events

What changed

Latest filing plus the most meaningful reported changes. Unchanged quarters are collapsed by default.

Q2 2026
Sold 0.8% of the position−1.21M shares · 149.49M shares remained
Filing context

Quarter-end price $251.64

Q1 2026
Baseline
Filing context

Quarter-end price $217.49

Q4 2025
Bought 3.6% more+5.20M shares · 151.17M shares reported after the change
Filing context

Quarter-end price $228.49

Q3 2025
Sold 1.0% of the position−1.48M shares · 145.98M shares remained
Filing context

Quarter-end price $231.54

Q2 2025
Bought 1.1% more+1.58M shares · 147.46M shares reported after the change
Filing context

Quarter-end price $185.62

Q1 2025
Bought 2.7% more+3.84M shares · 145.88M shares reported after the change
Filing context

Quarter-end price $209.52

Portfolio importance

How important is AbbVie in BlackRock, Inc.’s reported portfolio?

Relative importance is measured only within the verified primary non-option reported portfolio for each quarter.

Current portfolio weight0.6%Q2 2026
Current rank#26of 5696 reported positions
Peak portfolio weight0.7%Q4 2022
Best historical rank#19Q2 2022
SEC evidence & methodology

SEC filing evidence

Market context and filing-derived values are kept separate from actual transaction prices, which 13F filings do not disclose.

Latest verified stock price$264.482026-09-21

Market context only; not an investor transaction price.

Latest filing quarter-end price$251.64Q2 2026

Derived from validated reported value and shares where supported.

Latest verified investor filingQ2 2026 · filed 2026-08-07
Open SEC filing ↗

View AbbVie stock page →

Coverage is bounded to BlackRock’s top reported positions and material events rather than every security in each Form 13F. Source filings may contain additional securities, and 13F filings do not reveal exact trade dates or execution prices.